

Table S2. Projected Prevalence of CKD in 2020 and 2030 in Adults Aged 30 and Older, by Race

a. African-Americans

Stage	Current Prevalence ^a	2020	2030
	% (95% CI)	% (95% CI)	% (95% CI)
No CKD	86.78 (86.64–87.92)	85.29 (85.03–85.62)	84.97 (84.62–85.32)
CKD	13.22 (12.08–14.36)	14.71 (14.38–14.97)	15.03 (14.68–15.38)
Stage 1	3.20 (2.48–3.91)	4.06 (3.84–4.24)	3.56 (3.34–3.76)
Stage 2	2.90 (2.37–3.43)	3.73 (3.53–3.94)	4.07 (3.82–4.34)
Stage 3a	4.34 (3.80–4.89)	3.59 (3.48–3.72)	4.32 (4.13–4.49)
Stage 3b	1.58 (1.25–1.90)	1.66 (1.56–1.76)	1.74 (1.58–1.88)
Stage 4	1.21 (0.90–1.51)	0.85 (0.79–0.93)	0.60 (0.52–0.70)
Stage 5	—	0.82 (0.71–0.92)	0.73 (0.62–0.83)

b. Non-African-Americans

Stage	Current Prevalence ^a	2020	2030
	% (95% CI)	% (95% CI)	% (95% CI)
No CKD	86.80 (86.18–87.41)	85.69 (85.52–85.84)	83.09 (82.92–83.30)
CKD	13.20 (12.59–13.82)	14.31 (14.16–14.48)	16.91 (16.70–17.08)
Stage 1	1.97 (1.74–2.19)	2.11 (2.04–2.19)	1.59 (1.51–1.66)
Stage 2	3.04 (2.78–3.31)	3.46 (3.34–3.59)	4.10 (3.96–4.24)
Stage 3a	5.61 (5.18–6.04)	6.22 (6.13–6.30)	8.58 (8.44–8.72)
Stage 3b	1.95 (1.74–2.16)	1.93 (1.86–2.00)	2.01 (1.94–2.09)
Stage 4	0.64 (0.53–0.74)	0.47 (0.43–0.52)	0.49 (0.44–0.54)
Stage 5	—	0.13 (0.11–0.15)	0.14 (0.11–0.17)